Modulation of wild-type p53 activity by mutant p53 R273H depends on the p53 responsive element (p53RE). A comparative study between the p53REs of the MDM2, WAFI/Cip1 and Bax genes in the lung cancer environment

Anticancer Research

Volumn 19, Issue 1 A, 1999, Pages 579-587

  Zacharatos, P V ^d   Gorgoulis, V G ^d   Kotsinas, A ^d   Manolis, E N ^d   Liloglou, T ^a   Rassidakis, A N ^d   Kanavaros, P ^b   Field, J D ^a   Halazonetis, T ^c   Kittas, Ch ^d  

^a Roy Castle International Centre for Lung Cancer Research   (United Kingdom)

^b UNIVERSITY OF CRETE   (Greece)

^c WISTAR INSTITUTE   (United States)

^d NONE

Author keywords

Lung cancer; MDM2 p53RE; Mutant p53 R273H; p53; WAFI Cip1 p53RE Bax MDM2 p53RE

Indexed keywords

MUTANT PROTEIN; PROTEIN BAX; PROTEIN P53;

APOPTOSIS; ARTICLE; BAX GENE; CANCER CELL CULTURE; CELL CYCLE; CONTROLLED STUDY; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LUNG CANCER; LUNG NON SMALL CELL CANCER; PHENOTYPE; PRIORITY JOURNAL; PROTEIN CONFORMATION; RESPONSIVE ELEMENT;

BCL-2-ASSOCIATED X PROTEIN; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA; HUMANS; LUNG NEOPLASMS; MUTATION; NUCLEAR PROTEINS; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MDM2; RESPONSE ELEMENTS; TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032926306     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Oren M, Prives C:p53: upstream, downstream and offstream. Review of the 8th p53 workshop (Dundee, July 5-9, 1996). Bioch. et Bioph. Acta 1288: R13-R19, 1996.
2. Greenblatt MS, Bennett WP, Hollstein M, Harris CC: Mutations in the p53 tumour suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-4878, 1994.
3. Funk WD, Pak DT, Karas RH, Wright WE, Shay JW: A transcriptionally active DNA-binding site for human p53 protein complexes. Mol Cell Biol 12: 2866-2871, 1992.
4. Ko LJ, Prives C: p53: puzzle and paradigm. Genes and Development 10: 1054-1072, 1996.
5. Deffie A, Wu H, Reinke V, Lozano G: The tumor suppressor p53 regulates its own transcription. Mol Cell Biol 13: 3415-3423, 1993.
6. Gorgoulis VG, Zacharatos P, Manolis M, Ikonomopoulos JA, Damalas A, Lamprinopoulos C, Rassidakis GZ, Zoumpourlis V, Kotsinas A, Rassidakis AN, Halazonetis TD, Kittas C: Effects of p53 mutants derived from lung carcinomas on the p53-responsive element (p55RE) of the MDM2 gene. Br J Cancer 77(3): 374-84, 1998.
7. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parson R, Trent GM, Lin D, Merker WE, Kinz KW, Volgenstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825, 1993.
8. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Hoffman B, Lieberman D, Reed JC: Tumor suppressor p53 is a regulator of bcl-2 and bax in gene expression In vitro and in vivo Oncogene 9: 1799-805, 1994.
9. Deng EC, Nickoloff JA: Site-directed mutagenesis of virtually any plasmid by eliminating a unique restriction site. Anal Biochem 20: 81, 1992.
10. Sambrook J, Fritsh EF, Maniatis T: Molecular cloning. A laboratory manual. Plainview, NY. Cold Spring Harbor Laboratory, 1989.
11. Zauberman A, Flusberg D, Haupt Y, Barak Y, Oren M: A functional p53-responsive intronic promoter is contained within the human MDM2 gene. Nucleic Acids Res 23: 2584-2592, 1995.
12. El-Deiry WS, Tokino T, Waldman T, Oliner JD, Velculescu VE, Burrell M, Hill DE7 Healy E, Rees JL, Hamilton SR, Kinzler KW, Vogelstein B: Topological control of p21 expression in normal and neoplastic tissue. Cancer Res 55: 2910-9, 1995.
13. Miyashita T, Reed JC: Tumor suppressor p53 is a direct transcriptional activator of the human box gene. Cell 80: 293-9, 1995.
14. Halazonetis TD, Kandil AN: Conformational shifts propagate from the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants. EMBO J 12: 5057-5064, 1993.
15. Waterman MJF, Waterman JLF, Halazonetis TD: An engineered four-stranded coiled coil substitutes for the tetramerization domain of wild-type p53 and alleviates transdominant inhibition by tumor-derived p53 mutants. Cancer Res 56: 158-63, 1996.
16. Halazonetis TD: An enhancer "core" DNA-binding and transcriptional activity is induced upon transformation of rat embryo fibroblasts. Anticancer Res 12: 285-92, 1992.
17. Zakutt-Houri R, Bienz-Tadmor B, Givol D, Oren M: Human p53 cellular tumour antigen: cDNA sequence and expression in COS cells. EMBO J 4(5): 1251-1255, 1985.
18. Niewolik D, Vojtesek B, Kovarik J: p53 derived from human tumour cell lines and containing distinct point mutations can be activated to bind its consensus target sequence. Oncogene 10: 881-890, 1995.
19. Chen JY, Funk WD, Wright WE, Shay JW, Minna JD: Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences. Oncogene 8: 2159-66, 1993.
20. Dittmer D, Parti S, Zambetti G, Chu S, Teresky AK, Moore M, Finlay C, Levine AJ: Gain of function mutations in p53. Nature-Genet 4(1): 42-6, 1993.
21. Hinds PW, Finlay CA, Quartin RS, Baker SJ, Fearon ER, Vogelstein B, Levine AJ: Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes. Cell Growth Differ 1: 571-80, 1990.
22. Finlay CA, Hinds PW, Levine AJ: The p53 proto-oncogene can act as a suppressor of transformation. Cell 57: 1083-93, 1989.
23. Deb S, Jackson CT, Subler MA, Martin DW: Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells. J Virol 66: 6164-70, 1992.
24. Piette J, Neel H, Marechal V: MDM2: keeping p53 under control. Oncogene 15: 1001-10, 1997
25. Zhang W: Shay JW, Deisseroth A. Inactive p53 mutants may enhance the transcriptional activity of wt p53. Cancer Res 53: 4772-4775, 1993.
26. Cho Y, Gorina S, Jeffrey PD and Pavletich NP: Crystal Stucture of a p53 Tumour Suppressor-DNA Complex: Understanding Tumorigenic Mutations. Science 265: 346, 1994.
27. Miller CW, Chumacov A, Said J, Chen DL, Aiso A, Koeffler HP: Analysis of p53 transactivation through high-afinity binding sites. Oncogene 8: 1815-24, 1993.
28. Chumakov AM, Miller CW, Chen DL, Kocfflcr HP: Mutant p53 proteins have diverse intracellular abilities to oligomerize and activate transcription. Oncogene 8: 3005-11, 1993.
29. Bartek J, Iggo R, Gannon J, Lane DP: Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene 5: 893-9, 1990.
30. Stenger JE, Mayr JA, Mann K, Tegtmeyer P: Formation of stable homotetramers and multiples of tetramers. Mol Carcinog 5: 102-106, 1992.
31. Kawamura M, Yamashita T, Segawa K, Kaneuchi M, Shindoh M, Fujinaka K: The 273rd codon mutants of p53 show growth modulation activities not correlated with p53-specific transactivation activity. Oncogene 12: 2361-7, 1996.
32. Ludwig RL, Bates S, Vousden KH: Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function. Mol Cel Biol 4952-60, 1996.
33. Thut CJ, Chen JL, Klemin R, Tjian R: p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60. Science 267; 100-4. 1995.
34. Lu H, Levine AJ: Human TAF-31 is a transcriptional coactivator of the p53 protein. Proc Natl Acad Sci USA 92: 5154-8, 1995.
35. Wang XW, Yeh H, Schaeffer L, Roy R, Moncollin V, Egly J-M, Wang Z, Friedberg EC, Evans MK, Taffe BG et al: p53 modulation of TFIIH associated nucleotide excission repair activity. Nature Genet 10: 188-95, 1995.
36. Park DJ, Nakamura H, Chumakov AM, Said JW, Miller CW, Chen DL, Koeffler HP: Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines. Oncogene 9: 1899-1906, 1994.
37. Waldman T, Kinzler KW, Vogelstein B: p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 55: 5187-90, 1995.
38. Canman CE, Gilmer TM, Coutts SB, Kastan MB: Growth factor modulation of p53-mediated growth arrest versus apoptosis. Genes Dev 9: 600-11, 1995.
39. Haupt Y, Barak Y, Oren M: Cell type-specific inhibition of p53-mediated apoptosis by MDM2. EMBO J 15: 1596-606, 1996.
40. Macleod KF, Sherry N, Hannon G, Beach D, Tokino T, Kinzler K, Vogelstein B, Jacks T: p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev 9: 935-44, 1995.
41. Reed JC: Bcl-2 and the regulation of programmed cell death. J Cell Biol 124: 1-6, 1994.
42. Gorgoulis V, Zoumpourlis V, Rassidakis G, Karameris A, Rassidakis A, Spandidos D.A., Kittas C: A molecular and immunohistochemical study of the MDM2 protein isoforms and p53 gene product in bronchogenic carcinoma. J Path 180: 129-137, 1996
43. Martin K, Trouche D, Hagemeier S, Sorensen TS, La Thangue NB, Kouzarides T: Stimulation of E2F1/DP1 activity by MDM2 oncoprotein. Nature 375: 691-4, 1995.
44. Sigalas I, Calvert AH, Anderson JJ, Neal DE, Lunec J: Alternatively spliced MDM2 transcripts with loss of p53 binding domain sequences: Transforming ability and frequent detection in human cancer. Nature Med 2(8): 912-917, 1996.